Switch theme
Sign up to access all valuation multiples
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
1992
3.7K+
LTM Revenue $1.1B
LTM EBITDA $128M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Omnicell has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $128M.
In the most recent fiscal year, Omnicell achieved revenue of $1.1B and an EBITDA of $90.1M.
Omnicell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Omnicell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $474M | XXX | $471M | XXX | XXX | XXX |
| Gross Margin | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA | $128M | XXX | $90.1M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 8% | XXX | XXX | XXX |
| EBIT | $65.1M | XXX | $0.3M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | $67.6M | XXX | $12.5M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Omnicell's stock price is $30.
Omnicell has current market cap of $1.4B, and EV of $1.4B.
See Omnicell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.4B | XXX | XXX | XXX | XXX | $1.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Omnicell has market cap of $1.4B and EV of $1.4B.
Omnicell's trades at 1.3x EV/Revenue multiple, and 15.6x EV/EBITDA.
Equity research analysts estimate Omnicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Omnicell has a P/E ratio of 21.0x.
See valuation multiples for Omnicell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.0x | XXX | 15.6x | XXX | XXX | XXX |
| EV/EBIT | 21.6x | XXX | 4178.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.0x | XXX | 113.5x | XXX | XXX | XXX |
| EV/FCF | 47.3x | XXX | 10.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOmnicell's last 12 month revenue growth is 3%
Omnicell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Omnicell's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Omnicell's rule of X is 18% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Omnicell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | -2% | XXX | 39% | XXX | XXX | XXX |
| Rule of 40 | 8% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Omnicell acquired XXX companies to date.
Last acquisition by Omnicell was XXXXXXXX, XXXXX XXXXX XXXXXX . Omnicell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Omnicell founded? | Omnicell was founded in 1992. |
| Where is Omnicell headquartered? | Omnicell is headquartered in United States of America. |
| How many employees does Omnicell have? | As of today, Omnicell has 3.7K+ employees. |
| Who is the CEO of Omnicell? | Omnicell's CEO is Mr. Randall A. Lipps. |
| Is Omnicell publicy listed? | Yes, Omnicell is a public company listed on NAS. |
| What is the stock symbol of Omnicell? | Omnicell trades under OMCL ticker. |
| When did Omnicell go public? | Omnicell went public in 2001. |
| Who are competitors of Omnicell? | Similar companies to Omnicell include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Omnicell? | Omnicell's current market cap is $1.4B |
| What is the current revenue of Omnicell? | Omnicell's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Omnicell? | Omnicell revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Omnicell? | Current revenue multiple of Omnicell is 1.3x. |
| Is Omnicell profitable? | Yes, Omnicell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Omnicell? | Omnicell's last 12 months EBITDA is $128M. |
| What is Omnicell's EBITDA margin? | Omnicell's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of Omnicell? | Current EBITDA multiple of Omnicell is 11.0x. |
| What is the current FCF of Omnicell? | Omnicell's last 12 months FCF is $29.7M. |
| What is Omnicell's FCF margin? | Omnicell's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Omnicell? | Current FCF multiple of Omnicell is 47.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
